Followers | 44 |
Posts | 3169 |
Boards Moderated | 2 |
Alias Born | 01/18/2016 |
Thursday, April 04, 2024 3:30:01 PM
Amylyx Pharmaceuticals said it would voluntarily remove its drug for amyotrophic lateral sclerosis from the market, a rare move that comes less than a month after a clinical trial showed its once-promising treatment for the fatal disease doesn’t work.
https://www.washingtonpost.com/business/2024/04/04/amylyx-als-drug/
All my postings are verified and approved by my dog.
Recent COYA News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:26:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:20:17 PM
- Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results • Business Wire • 05/09/2024 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 09:21:04 PM
- Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium • Business Wire • 04/26/2024 12:15:00 PM
- Coya Therapeutics to Participate in the Mizuho Neuroscience Summit • Business Wire • 04/22/2024 12:15:00 PM
- Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit • Business Wire • 04/18/2024 12:15:00 PM
- Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium • Business Wire • 04/08/2024 12:15:00 PM
- Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results • Business Wire • 03/19/2024 12:15:00 PM
- Coya Therapeutics to Participate in BTIG Fireside Discussion • Business Wire • 03/12/2024 01:00:00 PM
- Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference • Business Wire • 03/12/2024 12:00:00 PM
- Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference • Business Wire • 03/06/2024 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:30 AM
- Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference • Business Wire • 02/29/2024 01:15:00 PM
- Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference • Business Wire • 02/22/2024 01:15:00 PM
- Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product” • Business Wire • 02/21/2024 01:15:00 PM
- Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases • Business Wire • 02/13/2024 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 01:00:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 01:00:12 AM
- Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference • Business Wire • 01/29/2024 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 11:30:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 11:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 11:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 01:15:28 PM
- Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series • Business Wire • 01/18/2024 01:15:00 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM